PSYCHIATRY, INCLUDING PSYCHEDELIC, CLINICAL TRIALS SITE OPENS IN PRIMARY CARE SETTING Novel therapies drive demand for new Paratus Clinical site
With
Megan Morrison,
Chief Executive Officer, Paratus Clinical
Professor Paul Fitzgerald,
Principal Investigator, Paratus Clinical &
Head of School of Medicine and Psychology, Australian National University
Bernadette Fitzgibbon
Director of Psychiatry Research, Paratus Clinical &
Associate Professor, Australian National University
AUSTRALIAN HEALTH JOURNAL SEGMENT
Filmed in Melbourne | August 2025
Over the past decade, Paratus has been involved in over 200 clinical trials across 4 clinical site locations. Now a fifth site, the newly opened Melbourne site will cater to both primary care and psychiatry, specifically designed for psychedelic studies.
The new Melbourne site will be a focused on primary care studies specifically expanding access to psychiatric research, a growing area of unmet need. Australian Health Journal met with 3 recent hires brought in to support clinical trials across the organisation and in psychiatry in Melbourne.
– Megan Morrison, the recently appointed CEO of Paratus Clinical has 24 years of clinical research experience, industry knowledge and leadership, having worked across sponsor, CRO, and now site-side roles.
– Professor Paul Fitzgerald, the Director of the Australian National University School of Medicine and Psychology, provides senior academic leadership at Paratus Clinical as the Principal Investigator. Professor Fitzgerald is a renowned psychiatrist and researcher with over 25 years of experience leading clinical trials focused on psychiatric disorders. His pioneering work includes the development and evaluation of innovative treatments such as neurostimulation therapies (like transcranial magnetic stimulation) and novel pharmacological approaches. He plays a central role in trials in pharmacological-assisted psychotherapy and psychedelic compounds.
With extensive experience in conducting clinical research in psychiatry, Fitzgerald mentors the trial staff and ensures the integrity of the research protocols.
– Bernadette Fitzgibbon, the Director of Psychiatry Research at Paratus Clinical and Associate Professor at the Australian National University, has two decades experience in clinical research. She previously served as Deputy Director of the Monarch Research Institute and is affiliated with both Monash University and the Australian National University, contributing to national research efforts across psychiatry and psychology. She will collaborate closely with Professor Fitzgerald in running clinical trials in Melbourne.
Talking to Australian Health Journal, both Fitzgerald and Fitzgibbon highlight the growing need for innovative treatments in mental health, one which Paratus aims to address through a focused approach to psychiatric research.
Source: Adapted from transcript and Paratus Clinical news posts
You Might also like
-
Allied Health Building Leadership Experience in Tasmania
A notable program run by Hospitals South is the ABLE program, or Allied Health Building Leadership Experience. This program was created to address the challenge of allied health professionals being seen as a single entity, rather than as individual disciplines, when it comes to leadership and management opportunities. The program is delivered entirely internally, with seminars presented by senior staff and mentorship opportunities for participants to become more effective representatives of allied health in meetings and working groups.
-
Gavin Fox-Smith talks Medical Technology
Former Johnson & Johnson ANZ Managing Director, Gavin Fox-Smith on working in large & small MedTech companies
-
1 million Australians with undiagnosed thyroid disorders remain at risk of irreparable damage
The Australian Thyroid Foundation is a national not-for-profit organisation with charity status aimed at patients and the healthcare community. The ATF’s focus is to support and educate its member base and promote our Good Thyroid Health Messaging throughout the Australian Community.
Australian Thyroid Foundation, CEO Beverley Garside attending the breakfast gave her response to the Federal Budget and the Foundation’s pre-budget submission, which was not granted.